Failure of the first biosimilar alternative to the high-cost drug Humira (adalimumab) to capture meaningful market share shows that formulary decisions by pharmacy benefit managers (PBMs) can substantially reduce the savings potential for patients of biosimilar drugs, according to health care consultants, but that could be changed by provisions of a Senate Finance Committee bill set to be marked up this week. Experts say Humira’s manufacturer AbbVie was able to keep biosimilars from capturing any significant market share by offering...